Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA; Adult AIDS Clinical Trial Group (ACTG) 301; 700 Teams; HIV MRS Consortium.

AIDS. 2007 Sep 12;21(14):1877-86.

PMID:
17721095
2.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
3.

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.

Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15.

PMID:
16861375
4.

Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.

Emre M, Mecocci P, Stender K.

J Alzheimers Dis. 2008 Jun;14(2):193-9.

PMID:
18560130
5.

Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy.

Brown ES, Vazquez M, Nakamura A.

Biol Psychiatry. 2008 Oct 15;64(8):727-9. doi: 10.1016/j.biopsych.2008.05.010. Epub 2008 Jun 25.

PMID:
18582848
6.

A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age.

Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Navia BA; HIV MRS Consortium.

Neuroimage. 2004 Dec;23(4):1336-47.

PMID:
15589098
7.

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.

Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM; Neurologic AIDS Research Consortium.

Neurology. 2002 Nov 26;59(10):1568-73.

PMID:
12451199
9.

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.

Pomara N, Ott BR, Peskind E, Resnick EM.

Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4.

PMID:
17334274
10.

Memantine induces reversible neurologic impairment in patients with MS.

Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J.

Neurology. 2009 May 12;72(19):1630-3. doi: 10.1212/01.wnl.0000342388.73185.80. Epub 2008 Dec 17.

PMID:
19092106
11.

A pilot double-blind treatment trial of memantine for alcohol dependence.

Evans SM, Levin FR, Brooks DJ, Garawi F.

Alcohol Clin Exp Res. 2007 May;31(5):775-82. Epub 2007 Mar 22.

PMID:
17378918
12.

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease.

Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL.

Alzheimers Dement. 2011 Jul;7(4):425-35. doi: 10.1016/j.jalz.2010.09.003. Epub 2011 Jun 8.

PMID:
21646051
13.

A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).

Ferris S, Schneider L, Farmer M, Kay G, Crook T.

Int J Geriatr Psychiatry. 2007 May;22(5):448-55.

PMID:
17117395
14.

Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial.

Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I, Skipka G, Zenz M, Tegenthoff M.

Pain. 2003 Jun;103(3):277-83.

PMID:
12791434
15.

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.

Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB; ACTG A5090 Team.

Neurology. 2007 Sep 25;69(13):1314-21. Epub 2007 Jul 25.

PMID:
17652642
16.

A 6-month, open-label study of memantine in patients with frontotemporal dementia.

Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A.

Int J Geriatr Psychiatry. 2008 Jul;23(7):754-9. doi: 10.1002/gps.1973.

PMID:
18213609
17.

Memantine in moderate-to-severe Alzheimer's disease.

Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group.

N Engl J Med. 2003 Apr 3;348(14):1333-41.

18.

Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials.

Sang CN, Booher S, Gilron I, Parada S, Max MB.

Anesthesiology. 2002 May;96(5):1053-61.

PMID:
11981142
19.

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.

Litvinenko IV, Odinak MM, Mogil'naya VI, Perstnev SV.

Neurosci Behav Physiol. 2010 Feb;40(2):149-55. doi: 10.1007/s11055-009-9244-1.

PMID:
20033305
20.

Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.

Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG.

Neurology. 1999 Jul 22;53(2):391-6.

PMID:
10430432

Supplemental Content

Support Center